Ironwood Cancer and Research Center

Chandler, Arizona 85224

2 studies enrolling now · 17 studies all time

What they study most

Adenocarcinoma of the Lung, Breast Cancer, Breast Neoplasms, Breast Tumor, Cancer of the Breast, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Estrogen Receptor- Negative Breast Cancer, HER2- Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Indolent Non-Hodgkin's Lymphomas, Locally Advanced Metastatic NSCLC

Studies at this site

• A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy — Recruiting now
• A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer — Recruiting now
• Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) — Running, not enrolling
• Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib — Running, not enrolling
• Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations — Running, not enrolling
• A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC — Running, not enrolling
• Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma — Stopped early
• Expanded Access of Sotorasib — NO_LONGER_AVAILABLE
• Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma — Status unconfirmed
• A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung — Completed
• Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) — Completed
• Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant — Stopped early
• Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas — Stopped early
• Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas — Stopped early
• Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer — Completed
• Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer — Completed
• A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer — Completed